Underwriter | Biotechnology Company | Date priced | Offering price per share** | 8/31/00 Share Price | Offering Gross (M)** | After-Market Performance (%) |
Adams, Harkness & Hill | Biopure Corp. (BPUR) | 3/13 | $35 | $16 | $87.5 | -54% |
Emisphere Technologies Inc. (EMIS) | 3/14 | $72.75 | $33 | $200.1 | -55% |
|
IntraBiotics Pharmaceuticals Inc. (IBPI) (IPO) | 3/27 | $15 | $21 | $112.5 | +40% |
|
Tanox Inc. (TNOX) (IPO) | 4/6 | $28.50 | $46.50 | $244.2 | +63% |
|
AtheroGenics Inc. (AGIX) (IPO) | 8/9 | $8 | $9.875 | $55.2 | +23% |
|
A.G. Edwards & Sons Inc. | AtheroGenics Inc. (AGIX) (IPO) | 8/9 | $8 | $9.875 | $55.2 | +23% |
Aragon Securities AB | Maxim Pharmaceuticals Inc. (MAXM) | 2/22 | $55 | $61.187 | $176.3 | +11% |
Bank of America Securities | SuperGen Inc. (SUPG) (Lead) | 3/16 | $45 | $19.687 | $90 | -56% |
Packard Bioscience Co. (PBSC) (IPO) | 4/19 | $9 | $19.875 | $111.24 | +121% |
|
EntreMed Inc. (ENMD)1 | 6/14 | $22 | $29.75 | $22 | +35% |
|
Regeneration Technologies Inc. (RTIX) (Lead, IPO) | 8/10 | $14 | $14.437 | $79.8 | +3% |
|
Bank Vontobel | Centaur Pharmaceuticals Inc. (Lead) | 3/30 | $11.50 | N/A | $21.9 | N/A |
Bear, Stearns & Co. Inc. | Diversa Corp. (DVSA) (Lead, IPO) | 2/14 | $24 | $28.50 | $200.1 | +19% |
Celera Genomics (NYSE:CRA) | 3/1 | $225 | $108 | $983.25 | -52% |
|
Bear, Stearns & Co. Inc. (Cont.) | Aviron (AVIR) | 4/4 | $22.50 | $45 | $51.75 | +100% |
Transgenomic Inc. (TBIO) (IPO) | 7/19 | $15 | $21 | $78.6 | +40% |
|
3-Dimensional Pharmaceuticals Inc. (DDDP) (Lead, IPO) | 8/4 | $15 | $38.875 | $86.25 | +159% |
|
Genaissance Pharmaceuticals Inc. (GNSC) (IPO) | 8/2 | $13 | $22.312 | $89.7 | +72% |
|
Chase H&Q | Gene Logic Inc. (GLGC) | 1/27 | $56 | $24.562 | $270 | -56% |
Sequenom Inc. (SQNM) (IPO) | 2/1 | $26 | $30.125 | $157 | +16% |
|
Genzyme Transgenics Corp. (GZTC) | 2/4 | $20 | $37.187 | $80.5 | +86% |
|
Diversa Corp. (DVSA) (IPO) | 2/14 | $24 | $28.50 | $200.1 | +19% |
|
Medarex Inc. (MEDX) | 3/3 | $172 | $110.50 | $412.7 | -36% |
|
Emisphere Technologies Inc. (EMIS) (Lead) | 3/14 | $72.75 | $33 | $200.1 | -55% |
|
Neose Technologies Inc. (NTEC) (Lead) | 3/16 | $32 | $41 | $73.6 | +28% |
|
Tularik Inc. (TLRK) | 3/22 | $35.125 | $33.375 | $100.1 | -5% |
|
InterMune Pharmaceuticals Inc. (ITMN) (IPO) | 3/24 | $20 | $38.062 | $125 | +90% |
|
Cubist Pharmaceuticals Inc. (CBST) | 4/6 | $33 | $61.125 | $94.9 | 85% |
|
Ribozyme Pharmaceuticals Inc. (RZYM) | 4/6 | $18 | $28.875 | $65.2 | +60% |
|
Chase H&Q (Cont.) | Sangamo BioSciences Inc. (SGMO) (IPO) | 4/6 | $15 | $49.25 | $52.5 | +228% |
Packard Bioscience Co. (PBSC) (IPO) | 4/19 | $9 | $19.875 | $111.24 | +121% |
|
Paradigm Genetics Inc. (PDGM) (Lead, IPO) | 5/5 | $7 | $16.50 | $47.25 | +136% |
|
Transgenomic Inc. (TBIO) (Lead, IPO) | 7/19 | $15 | $21 | $78.6 | +40% |
|
Variagenics Inc. (VGNX) (IPO) | 7/21 | $14 | $28.25 | $80.5 | +102% |
|
Gemini Genomics plc (UK; GMNI) (IPO) | 7/25 | $14 | $17.50 | $96.6 | +25% |
|
Discovery Part- ners International Inc. (DPII) (Co-lead, IPO) | 7/27 | $18 | $20.875 | $103.5 | +16% |
|
Genencor International Inc. (GCOR) (IPO) | 7/27 | $18 | $31.125 | $144.9 | +73% |
|
Illumina Inc. (ILMN) (IPO) | 7/27 | $16 | $44.75 | $96 | +180% |
|
3-Dimensional Pharmaceuticals Inc. (DDDP) (IPO) | 8/4 | $15 | $38.875 | $86.25 | +159% |
|
Inspire Pharmaceuticals Inc. (ISPH) (IPO) | 8/3 | $12 | $17.50 | $75.9 | +46% |
|
Versicor Inc. (VERS) (IPO) | 8/3 | $11 | $11.687 | $58.2 | +6% |
|
AtheroGenics Inc. (AGIX) (Lead, IPO) | 8/9 | $8 | $9.875 | $55.2 | +23% |
|
Chase H&Q (Cont.) | Pharsight Corp. (PHST) (IPO) | 8/9 | $10 | $9.625 | $30 | -4% |
Esperion Therapeutics Inc. (ESPR) (IPO) | 8/10 | $9 | $16.062 | $62.1 | +78% |
|
Large Scale Biology Corp. (LSBC) (IPO) | 8/10 | $17 | $30.906 | $97.75 | +82% |
|
Telik Inc. (TELK) (IPO) | 8/16 | $7 | $10.187 | $40.25 | +46% |
|
CIBC World Markets | Enzon Inc. (ENZN) | 3/21 | $44.50 | $60.875 | $102.4 | +37% |
Tanox Inc. (TNOX) (Lead, IPO) | 4/6 | $28.50 | $46.50 | $244.2 | +63% |
|
Lexicon Genetics Inc. (LEXG) (IPO) | 4/7 | $22 | $33.25 | $220 | +51% |
|
Avigen Inc. (AVGN) | 4/13 | $26 | $36.437 | $29.9 | +40% |
|
Praecis Pharmaceuticals Inc. (PRCS) (IPO) | 4/26 | $10 | $43.812 | $92 | +338% |
|
ViroLogic Inc. (VLGC) (Lead, IPO) | 5/2 | $7 | $20.375 | $35 | +191% |
|
Pain Therapeutics Inc. (PTIE) (IPO) | 7/13 | $12 | $19.25 | $69 | +60% |
|
Applied Molecular Evolution Inc. (AMEV) (Lead, IPO) | 7/26 | $19 | $32.187 | $101.6 | +69% |
|
The Medicines Co. (MDCO) (IPO) | 8/8 | $16 | $25 | $110.4 | +56% |
|
Ista Pharmaceuticals Inc. (ISTA) (Lead, IPO) | 8/22 | $10.50 | $13.187 | $31.5 | +26% |
|
Credit Suisse First Boston | Maxygen Inc. (MAXY) | 3/20 | $97 | $53.75 | $145.5 | -45% |
Aradigm Corp. (ARDM) (Lead) | 3/29 | $16 | $17.875 | $46 | +12% |
|
Lexicon Genetics Inc. (LEXG) (Co-lead, IPO) | 4/7 | $22 | $33.25 | $220 | +51% |
|
Exelixis Pharmaceuticals Inc. (EXEL) (IPO) | 4/10 | $13 | $45 | $136 | +246% |
|
Praecis Pharmaceuticals Inc. (PRCS) (IPO) | 4/26 | $10 | $43.812 | $92 | +338% |
|
Orchid BioSciences Inc. (ORCH) (Lead, IPO) | 5/4 | $8 | $44.937 | $55.2 | +462% |
|
Variagenics Inc. (VGNX) (Lead, IPO) | 7/21 | $14 | $28.25 | $80.5 | +102% |
|
Genencor International Inc. (GCOR) (IPO) | 7/27 | $18 | $31.125 | $144.9 | +73% |
|
Dain, Rauscher Wessels | Gene Logic Inc. (GLGC) | 1/27 | $56 | $24.56 | $270 | -56% |
Medarex Inc. (MEDX) | 3/3 | $172 | $110.50 | $412.7 | -36% |
|
Nanogen Inc. (NGEN) | 3/16 | $55 | $24.125 | $82.5 | -56% |
|
Luminex Corp. (LMNX) (IPO) | 3/30 | $17 | $40 | $82.8 | +135% |
|
Genomic Solutions Inc. (GNSL) (IPO) | 5/5 | $8 | $15.937 | $64.4 | +99% |
|
Transgenomic Inc. (TBIO) (IPO) | 7/19 | $15 | $21 | $78.6 | +40% |
|
Deutsche Banc Alex. Brown | Sequenom Inc. (SQNM) (IPO) | 2/1 | $26 | $30.125 | $157 | +16% |
Diversa Corp. (DVSA) (IPO) | 2/14 | $24 | $28.50 | $200.1 | +19% |
|
Emisphere Technologies Inc. (EMIS) | 3/14 | $72.75 | $33 | $200.1 | -55% |
|
Aclara Biosciences Inc. (ACLA) (Co-lead, IPO) | 3/20 | $21 | $39 | $217.4 | +86% |
|
Angiotech Pharmaceuticals Inc. (Canada; ANPI)2 (Joint Lead) | 3/22 | $53.50 | $45.25 | $93.6 | -15.4% |
|
IntraBiotics Pharmaceuticals Inc. (IBPI) (Lead, IPO) | 3/27 | $15 | $21 | $112.5 | +40% |
|
Genaissance Pharmaceuticals Inc. (GNSC) (Lead, IPO) | 8/2 | $13 | $22.312 | $89.7 | +72% |
|
Inspire Pharmaceuticals Inc. (ISPH) (Lead, IPO) | 8/3 | $12 | $17.50 | $75.9 | +46% |
|
Lion Bioscience AG (Germany; LEON) (Joint lead, IPO) | 8/10 | $39.68 | $87.375 | $210.3 | +120% |
|
DLJ Direct Inc. | Charles River Laboratories Corp. (NYSE:CRL) (IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
Pharsight Corp. (PHST) (IPO) | 8/9 | $10 | $9.625 | $30 | -4% |
|
Donaldson, Lufkin & Jenrette | Charles River Laboratories Corp. (NYSE: CRL) (Co-lead, IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
Pharsight Corp. (PHST) (Lead, IPO) | 8/9 | $10 | $9.625 | $30 | -4% |
|
Fidelity Capital Markets | Versicor Inc. (VERS) (IPO) | 8/3 | $11 | $11.687 | $58.2 | +6% |
Rosetta Inpharmatics Inc. (RSTA) (IPO) | 8/4 | $14 | $35.375 | $115.9 | +153% |
|
Telik Inc. (TELK) | 8/16 | $7 | $10.187 | $40.25 | +46% |
|
First Colonial Securities First Union Securities Inc. | AVI BioPharma Inc. (AVII) | 7/27 | $7.25 | $9.187 | $21.75 | +27% |
Vical Inc. (VICL) | 1/21 | $36.50 | $24.50 | $125.9 | -33% |
|
Nanogen Inc. (NGEN) | 3/16 | $55 | $24.125 | $82.5 | -56% |
|
Texas Biotechnology Corp. (AMEX: TXB) | 4/6 | $12.50 | $17.625 | $71.875 | +41% |
|
First Security Van Kasper | The Immune Response Corp. (IMNR) (Lead) | 8/8 | $6 | $9 | $16.6 | +50% |
Gerard Klauer Mattison & Co. | OraPharma Inc. (OPHM) (IPO) | 3/9 | $18 | $11.375 | $82.8 | -37% |
Goldman, Sachs & Co. | Vical Inc. (VICL) (Lead) | 1/21 | $36.50 | $24.50 | $125.9 | -33% |
Celera Genomics (NYSE:CRA) (Co-lead) | 3/1 | $225 | $108 | $983.25 | -52% |
|
Maxygen Inc. (MAXY) (Lead) | 3/20 | $97 | $53.75 | $145.5 | -45% |
|
Genentech Inc. (NYSE:DNA) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
Exelixis Pharmaceuticals Inc. (EXEL) (Lead, IPO) | 4/10 | $13 | $45 | $136 | +246% |
|
Illumina Inc. (ILMN) (Lead, IPO) | 7/27 | $16 | $44.75 | $96 | +180% |
|
Gruntal & Co. LLC | Keryx Biopharmaceuticals Inc. (Israel; KERX)3 (IPO) | 7/28 | $10 | $13.875 | $52 | +39% |
The Immune Response Corp. (IMNR) | 8/8 | $6 | $9 | $16.6 | +50% |
|
I-Bankers Securities Inc. | AVI BioPharma Inc. (AVII) | 7/27 | $7.25 | $9.1875 | $21.75 | +27% |
ING Barings LLC | Gene Logic Inc. (GLGC) (Lead) | 1/27 | $56 | $24.56 | $270 | -56% |
Celera Genomics (NYSE:CRA) | 3/1 | $225 | $108 | $983.25 | -52% |
|
Cubist Pharmaceuticals Inc. (CBST) | 4/6 | $33 | $61.125 | $94.9 | +85% |
|
Ribozyme Pharmaceuticals Inc. (RZYM) (Lead) | 4/6 | $18 | $28.875 | $65.2 | +60% |
|
Sangamo BioSciences Inc. (SGMO) (IPO) | 4/6 | $15 | $49.25 | $52.5 | +228% |
|
Avigen Inc. (AVGN) | 4/13 | $26 | $36.437 | $29.9 | +40% |
|
ViroLogic Inc. (VLGC) (IPO) | 5/2 | $7 | $20.375 | $35 | +191% |
|
Charles River Laboratories Inc. (NYSE:CRL) (IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
|
Argonaut Technologies Inc. (AGNT) (IPO) | 7/24 | $15 | $17.375 | $79.35 | +16% |
|
Arena Pharmaceuticals Inc. (ARNA) (Lead, IPO) | 7/28 | $18 | $46.25 | $124.2 | +157% |
|
Invemed Associates | Maxygen Inc. (MAXY) | 3/20 | $97 | $53.75 | $145.5 | -45% |
Aradigm Corp. (ARDM) | 3/29 | $16 | $17.875 | $46 | +12% |
|
Cepheid (CPHD) (IPO) | 6/21 | $6 | $12.125 | $34.5 | +102% |
|
Compugen Ltd. (Israel; CGEN) (IPO) | 8/14 | $10 | $15.75 | $57.5 | +58% |
|
J.P. Morgan & Co. | Celgene Corp. (CELG) (Co-lead) | 2/10 | $33.67 | $74 | $348.45 | +120% (Split adjusted)4 |
Maxim Pharmaceuticals Inc. (MAXM) (Lead) | 2/22 | $55 | $61.187 | $176.3 | +11% |
|
Biopure Corp. (BPUR) (Lead) | 3/13 | $35 | $16 | $87.5 | -54% |
|
Tularik Inc. (TLRK) | 3/22 | $35.125 | $33.375 | $100.1 | -5% |
|
Genentech Inc. (NYSE:DNA) (Lead) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
Regeneron Pharmaceuticals Inc. (REGN) | 3/29 | $29.75 | $35.437 | $77.35 | +19% |
|
Lexicon Genetics Inc. (LEXG) (Co-lead, IPO) | 4/7 | $22 | $33.25 | $220 | +51% |
|
Paradigm Genetics Inc. (PDGM) (IPO) | 5/5 | $7 | $16.50 | $47.25 | +136% |
|
The Medicines Co. (MDCO) (Lead, IPO) | 8/8 | $16 | $25 | $110.4 | +56% |
|
Large Scale Biology Corp. (LSBC) (Lead, IPO) | 8/10 | $17 | $30.906 | $97.75 | +82% |
|
Dyax Corp. (DYAX) (Lead, IPO) | 8/15 | $15 | $35 | $69 | +133% |
|
KBC Securities | Tanox Inc. (TNOX) (IPO) | 4/6 | $28.50 | $46.50 | $244.2 | +63% |
Lazard Freres & Co. LLC | Cubist Pharmaceuticals Inc. (CBST) | 4/6 | $33 | $61.125 | $94.9 | +85% |
Rosetta Inpharmatics Inc. (RSTA) (IPO) | 8/4 | $14 | $35.375 | $115.9 | +153% |
|
Legg Mason Wood Walker | Telik Inc. (TELK) (IPO) | 8/16 | $7 | $10.187 | $40.25 | +46% |
Lehman Brothers Inc. | Abgenix Inc. (ABGX) | 2/11 | $52.50 | $75.171 | $724.46 | +43% (Split adjusted)5 |
Nanogen Inc. (NGEN) | 3/16 | $55 | $24.125 | $82.5 | -56% |
|
SuperGen Inc. (SUPG) | 3/16 | $45 | $19.69 | $90 | -56% |
|
Tularik Inc. (TLRK) (Lead) | 3/22 | $35.125 | $33.375 | $100.1 | -5% |
|
Genentech Inc. (NYSE:DNA) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
Regeneron Pharmaceuticals Inc. (REGN) | 3/29 | $29.75 | $35.437 | $77.35 | +19% |
|
Luminex Corp. (LMNX) (IPO) | 3/30 | $17 | $40 | $82.8 | +135% |
|
Sangamo BioSciences Inc. (SGMO) (Lead, IPO) | 4/6 | $15 | $49.25 | $52.5 | +228% |
|
Corixa Corp. (CRXA) | 4/7 | $32 | $51.187 | $64 | +60% |
|
Genomic Solutions Inc. (GNSL) (IPO) | 5/5 | $8 | $15.937 | $64.4 | +99% |
|
Charles River Laboratories Corp. (NYSE:CRL) (Co-lead, IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
|
Decode Genetics Genetics Inc. (Iceland; DCGN) (IPO) | 7/21 | $18 | $27.625 | $198.7 | +53% |
|
Discovery Partners International Inc. (DPII) (Co-lead, IPO) | 7/27 | $18 | $20.875 | $103.5 | +16% |
|
Lehman Brothers Inc. (Cont.) | Versicor Inc. (VERS) (Lead, IPO) | 8/3 | $11 | $11.687 | $58.2 | +6% |
Rosetta Inpharmatics Inc. (RSTA) (Lead, IPO) | 8/4 | $14 | $35.375 | $115.9 | +153% |
|
Regeneration Technologies Inc. (RTIX) (IPO) | 8/10 | $14 | $14.437 | $79.8 | +3% |
|
Dyax Corp. (DYAX) (IPO) | 8/15 | $15 | $35 | $69 | +133% |
|
Telik Inc. (TELK) (Lead, IPO) | 8/16 | $7 | $10.187 | $40.25 | +46% |
|
Merrill Lynch & Co. | Abgenix Inc. (ABGX) | 2/11 | $52.50 | $75.171 | $724.46 | +43% (Split adjusted)5 |
Angiotech Pharmaceuticals Inc. (Canada; ANPI)2 (Joint Lead) | 3/22 | $53.50 | $45.25 | $93.6 | -15.4% |
|
Genentech Inc. (NYSE:DNA) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
Regeneron Pharmaceuticals Inc. (REGN) (Lead) | 3/29 | $29.75 | $35.437 | $77.35 | +19% |
|
Packard Bioscience Co. (PBSC) (Lead, IPO) | 4/19 | $9 | $19.875 | $111.24 | +121% |
|
Genencor International Inc. (GCOR) (Lead, IPO) | 7/27 | $18 | $31.125 | $144.9 | +73% |
|
Morgan Stanley Dean Witter Inc. | Celera Genomics (NYSE:CRA) (Co-lead) | 3/1 | $225 | $108 | $983.25 | -52% |
Medarex Inc. (MEDX) (Lead) | 3/3 | $172 | $110.50 | $412.7 | -36% |
|
Enzon Inc. (ENZN) (Lead) | 3/21 | $44.50 | $60.875 | $102.4 | +37% |
|
Aviron (AVIR) (Lead) | 4/4 | $22.50 | $45 | $51.75 | +100% |
|
Decode Genetics Inc. (Iceland; DCGN) (Lead, IPO) | 7/21 | $18 | $27.625 | $198.7 | +53% |
|
Lion Bioscience AG (Germany; LEON) (Lead, IPO) | 8/10 | $39.68 | $87.375 | $210.3 | +120% |
|
Neidiger Tucker Bruner Inc. | Entropin Inc. (OTC BB:ETOP) (Lead) | 3/21 | $7.25 | $8.625 | $16.2 | +19% |
Nomura International | Diacrin Inc. (DCRN) | 3/22 | $11.50 | $9.062 | $39.7 | -21% |
Pacific Growth Equities Inc. | Abgenix Inc. (ABGX) | 2/11 | $52.50 | $75.171 | $724.46 | +43% (Split adjusted)5 |
Nanogen Inc. (NGEN) | 3/16 | $55 | $24.125 | $82.5 | -56% |
|
Cubist Pharmaceuticals Inc. (CBST) | 4/6 | $33 | $61.125 | $94.9 | +85% |
|
Corixa Corp. (CRXA) | 4/7 | $32 | $51.187 | $64 | +60% |
|
Paradigm Genetics Inc. (PDGM) (IPO) | 5/5 | $7 | $16.50 | $47.25 | +136% |
|
Dendreon Corp. (DNDN) (IPO) | 6/16 | $10 | $20.50 | $48.9 | +105% |
|
Charles River Laboratories Corp. (NYSE: CRL) (IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
|
Versicor Inc. (VERS) (IPO) | 8/3 | $11 | $11.687 | $58.2 | +6% |
|
Dyax Corp. (DYAX) (IPO) | 8/15 | $15 | $35 | $69 | +133% |
|
PaineWebber Inc. | Diacrin Inc. (DCRN) (Lead) | 3/22 | $11.50 | $9.062 | $39.7 | -21% |
PaineWebber Inc. (Cont.) | Visible Genetics Inc. (VGIN) | 3/29 | $38 | $47.875 | $79.42 | +26% |
Texas Biotechnology Corp. (AMEX: TXB) (Lead) | 4/6 | $12.50 | $17.625 | $71.875 | +41% |
|
Applied Molecular Evolution Inc. (AMEV) (IPO) | 7/26 | $19 | $32.187 | $101.6 | +69% |
|
Paulson Investment Co. | AVI BioPharma Inc. (AVII) (Lead) | 7/27 | $7.25 | $9.187 | $21.75 | +27% |
Prudential Vector Healthcare Group | Celgene Corp. (CELG) (Co-lead) | 2/10 | $33.67 | $74 | $348.45 | +120% (Split adjusted)4 |
Maxim Pharmaceuticals Inc. (MAXM) | 2/22 | $55 | $61.187 | $176.3 | +11% |
|
Neose Technologies Inc. (NTEC) | 3/16 | $32 | $41 | $73.6 | +28% |
|
SuperGen Inc. (SUPG) | 3/16 | $45 | $19.687 | $90 | -56% |
|
Allos Therapeutics Inc. (ALTH) (IPO) | 3/28 | $18 | $11.75 | $90 | -35% |
|
InterMune Pharmaceuticals Inc. (ITMN) (IPO) | 3/24 | $20 | $38.062 | $125 | +90% |
|
Texas Biotechnology Corp. (AMEX: TXB) | 4/6 | $12.50 | $17.625 | $71.875 | +41% |
|
Corixa Corp. (CRXA) | 4/7 | $32 | $51.187 | $64 | +60% |
|
ViroLogic Inc. (VLGC) (IPO) | 5/2 | $7 | $20.375 | $35 | +191% |
|
Dendreon Corp. (DNDN) (Lead, IPO) | 6/16 | $10 | $20.50 | $48.9 | +105% |
|
Cepheid (CPHD) (IPO) | 6/21 | $6 | $12.125 | $34.5 | +102% |
|
Arena Pharmaceuticals Inc. (ARNA) (IPO) | 7/28 | $18 | $46.25 | $124.2 | +157% |
|
Rosetta Inpharmatics Inc. (RSTA) (IPO) | 8/4 | $14 | $35.375 | $115.9 | +153% |
|
Ista Pharmaceuticals Inc. (ISTA) (IPO) | 8/22 | $10.50 | $13.187 | $31.5 | +26% |
|
Punk Ziegel & Co. | Lexicon Genetics Inc. (LEXG) (IPO) | 4/7 | $22 | $33.25 | $220 | +51% |
Robertson Stephens Inc. | Vical Inc. (VICL) | 1/21 | $36.50 | $24.50 | $125.9 | -33% |
Gene Logic Inc. (GLGC) | 1/27 | $56 | $24.56 | $270 | -56% |
|
Antigenics LLC (AGEN) (IPO) | 2/3 | $18 | $16.875 | $72.5 | -6% |
|
Abgenix Inc. (ABGX) (Lead) | 2/11 | $52.50 | $75.171 | $724.46 | +43% (Split adjusted)5 |
|
OraPharma Inc. (OPHM) (Lead, IPO) | 3/9 | $18 | $11.375 | $82.8 | -37% |
|
Maxygen Inc. (MAXY) | 3/20 | $97 | $53.75 | $145.5 | -45% |
|
Genentech Inc. (NYSE:DNA) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
Regeneron Pharmaceuticals Inc. (REGN) | 3/29 | $29.75 | $35.437 | $77.35 | +19% |
|
Visible Genetics Inc. (VGIN) (Lead) | 3/29 | $38 | $47.875 | $79.42 | +26% |
|
Tanox Inc. (TNOX) (IPO) | 4/6 | $28.50 | $46.50 | $244.2 | +63% |
|
Cubist Pharmaceuticals Inc. (CBST) (Lead) | 4/6 | $33 | $61.125 | $94.9 | +85% |
|
Robertson Stephens Inc. (Cont.) | Orchid BioSciences Inc. (ORCH) (IPO) | 5/4 | $8 | $44.937 | $55.2 | +462% |
Deltagen Inc. (DGEN) (Co-lead, IPO) | 8/3 | $15 | $28.875 | $120.4 | +93% |
|
The Medicines Co. (MDCO) (Co-lead, IPO) | 8/8 | $16 | $25 | $110.4 | +56% |
|
AtheroGenics Inc. (AGIX) (IPO) | 8/9 | $8 | $9.875 | $55.2 | +23% |
|
Esperion Therapeutics Inc. (ESPR) (Lead, IPO) | 8/10 | $9 | $16.062 | $62.1 | +78% |
|
Compugen Ltd. (Israel; CGEN) (Lead, IPO) | 8/14 | $10 | $15.75 | $57.5 | +58% |
|
Robert W. Baird & Co. | Biopure Corp. (BPUR) | 3/13 | $35 | $16 | $87.5 | -54% |
Packard Bioscience Co. (PBSC) (IPO) | 4/19 | $9 | $19.875 | $111.24 | +121% |
|
Roth Capital Partners Inc. | Visible Genetics Inc. (VGIN) | 3/29 | $38 | $47.875 | $79.42 | +26% |
Keryx Biopharmaceuticals Inc. (Israel; KERX)3 (IPO) (U.S. lead) | 7/28 | $10 | $13.875 | $52 | +39% |
|
Salomon Smith Barney | Biopure Corp. (BPUR) | 3/13 | $35 | $16 | $87.5 | -54% |
Avigen Inc. (AVGN) (Lead) | 4/13 | $26 | $36.437 | $29.9 | +40% |
|
Praecis Pharmaceuticals Inc. (PRCS) (Lead, IPO) | 4/26 | $10 | $43.812 | $92 | +338% |
|
Orchid BioSciences Inc. (ORCH) (IPO) | 5/4 | $8 | $44.937 | $55.2 | +462% |
|
Genencor International Inc. (GCOR) (IPO) | 7/27 | $18 | $31.125 | $144.9 | +73% |
|
Genaissance Pharmaceuticals Inc. (GNSC) (IPO) | 8/2 | $13 | $22.312 | $89.7 | +72% |
|
Deltagen Inc. (DGEN) (Co-lead, IPO) | 8/3 | $15 | $28.875 | $120.4 | +93% |
|
Sanders Morris Harris | Texas Biotechnology Corp. (AMEX: TXB) | 4/6 | $12.50 | $17.625 | $71.875 | +41% |
S.G. Cowen Securities Corp. | Vical Inc. (VICL) | 1/21 | $36.50 | $24.50 | $125.9 | -33% |
Celera Genomics (NYSE:CRA) | 3/1 | $225 | $108 | $983.25 | -52% |
|
Enzon Inc. (ENZN) | 3/21 | $44.50 | $60.875 | $102.4 | +37% |
|
IntraBiotics Pharmaceuticals Inc. (IBPI) (IPO) | 3/27 | $15 | $21 | $112.5 | +40% |
|
Allos Therapeutics Inc. (ALTH) (Lead, IPO) | 3/28 | $18 | $11.75 | $90 | -35% |
|
Aradigm Corp. (ARDM) | 3/29 | $16 | $17.875 | $46 | +12% |
|
Exelixis Pharmaceuticals Inc. (EXEL) (IPO) | 4/10 | $13 | $45 | $136 | +246% |
|
Dendreon Corp. (DNDN) (IPO) | 6/16 | $10 | $20.50 | $48.9 | +105% |
|
Charles River Laboratories Corp. (NYSE: CRL) (IPO) | 6/23 | $16 | $27.437 | $257.6 | +71% |
|
Variagenics Inc. (VGNX) (IPO) | 7/21 | $14 | $28.25 | $80.5 | +102% |
|
Argonaut Technologies Inc. (AGNT) (IPO) | 7/24 | $15 | $17.375 | $79.35 | +16% |
|
Gemini Genomics plc (UK:GMNI) (Lead, IPO) | 7/25 | $14 | $17.50 | $96.6 | +25% |
|
Applied Molecular Evolution Inc. (AMEV) (IPO) | 7/26 | $19 | $32.187 | $101.6 | +69% |
|
Illumina Inc. (ILMN) (IPO) | 7/27 | $16 | $44.75 | $96 | +180% |
|
Arena Pharmaceuticals Inc. (ARNA) | 7/28 | $18 | $46.25 | $124.2 | +157% |
|
Stephens Inc. | Paradigm Genetics Inc. (PDGM) (IPO) | 5/5 | $7 | $16.50 | $47.25 | +136% |
Regeneration Technologies Inc. (RTIX) (IPO) | 8/10 | $14 | $14.437 | $79.8 | +3% |
|
Thomas Weisel Partners LLC | Tularik Inc. (TLRK) | 3/22 | $35.125 | $33.375 | $100.1 | -5% |
Packard Bioscience Co. (PBSC) (IPO) | 4/19 | $9 | $19.875 | $111.24 | +121% |
|
Pain Therapeutics Inc. (PTIE) (Lead, IPO) | 7/13 | $12 | $19.25 | $69 | +60% |
|
Ista Pharmaceuticals Inc. (ISTA) (IPO) | 8/22 | $10.50 | $13.187 | $31.5 | +26% |
|
Tucker Anthony Cleary Gull/ Tucker Anthony Inc. | Genome Therapeutics Corp. (GENE)6 | 7/10 | $31.01 | $25.125 | $46.5 | -19% |
Pain Therapeutics Inc. (PTIE) (IPO) | 7/13 | $12 | $19.25 | $69 | +60% |
|
UBS Warburg/ Warburg Dillon Read LLC | Sequenom Inc. (SQNM) (Lead, IPO) | 2/1 | $26 | $30.125 | $157 | +16% |
Genzyme Transgenics Corp. (GZTC) (Lead) | 2/4 | $20 | $37.187 | $80.5 | +86% |
|
Medarex Inc. (MEDX) | 3/3 | $172 | $110.50 | $412.7 | -36% |
|
Emisphere Technologies Inc. (EMIS) | 3/14 | $72.75 | $33 | $200.1 | -55% |
|
Nanogen Inc. (NGEN) (Lead) | 3/16 | $55 | $24.125 | $82.5 | -56% |
|
Neose Technologies Inc. (NTEC) | 3/16 | $32 | $41 | $73.6 | +28% |
|
SuperGen Inc. (SUPG) | 3/16 | $45 | $19.687 | $90 | -56% |
|
Aclara Biosciences Inc. (ACLA) (Co-lead, IPO) | 3/20 | $21 | $39 | $217.4 | +86% |
|
Tularik Inc. (TLRK) | 3/22 | $35.125 | $33.375 | $100.1 | -5% |
|
Genentech Inc. (NYSE:DNA) | 3/23 | $163 | $190.50 | $2,819.9 | +17% |
|
InterMune Pharmaceuticals Inc. (ITMN) (Lead, IPO) | 3/24 | $20 | $38.062 | $125 | +90% |
|
IntraBiotics Pharmaceuticals Inc. (IBPI) (IPO) | 3/27 | $15 | $21 | $112.5 | +40% |
|
Aradigm Corp. (ARDM) | 3/29 | $16 | $17.875 | $46 | +12% |
|
Visible Genetics Inc. (VGIN) | 3/29 | $38 | $47.875 | $79.42 | +26% |
|
Luminex Corp. (LMNX) (Lead, IPO) | 3/30 | $17 | $40 | $82.8 | +135% |
|
Tanox Inc. (TNOX) (IPO) | 4/6 | $28.50 | $46.50 | $244.2 | +63% |
|
Corixa Corp. (CRXA) (Lead) | 4/7 | $32 | $51.187 | $64 | +60% |
|
Genomic Solutions Inc. (GNSL) (Lead, IPO) | 5/5 | $8 | $15.937 | $64.4 | +99% |
|
Cepheid (CPHD) (Lead, IPO) | 6/21 | $6 | $12.125 | $34.5 | +102% |
|
Argonaut Technologies Inc. (AGNT) (Lead, IPO) | 7/24 | $15 | $17.375 | $79.35 | +16% |
|
Discovery Partners International Inc. (DPII) (IPO) | 7/27 | $18 | $20.875 | $103.5 | +16% |
|
Genaissance Pharmaceuticals Inc. (GNSC) (IPO) | 8/2 | $13 | $22.312 | $89.7 | +72% |
|
Versicor Inc. (VERS) (IPO) | 8/3 | $11 | $11.687 | $58.2 | +6% |
|
Telik Inc. (TELK) (IPO) | 8/16 | $7 | $10.187 | $40.25 | +46% |
|
U.S. Bancorp Piper Jaffray | Antigenics LLC (AGEN) (Lead, IPO) | 2/3 | $18 | $16.875 | $72.5 | -6% |
Celgene Corp. (CELG) | 2/10 | $33.67 | $74 | $348.45 | +120% (Split adjusted)4 |
|
OraPharma Inc. (OPHM) (IPO) | 3/9 | $18 | $11.375 | $82.8 | -37% |
|
Neose Technologies Inc. (NTEC) | 3/16 | $32 | $41 | $73.6 | +28% |
|
Aclara Biosciences Inc. (ACLA) (IPO) | 3/20 | $21 | $39 | $217.4 | +86% |
|
Angiotech Pharmaceuticals Inc. (Canada; ANPI)2 | 3/22 | $53.50 | $45.25 | $93.6 | -15.4% |
|
Allos Therapeutics Inc. (ALTH) (IPO) | 3/28 | $18 | $11.75 | $90 | -35% |
|
Aviron (AVIR) | 4/4 | $22.50 | $45 | $51.75 | +100% |
|
Deltagen Inc. (DGEN) (IPO) | 8/3 | $15 | $28.875 | $120.4 | +93% |
|
Inspire Pharmaceuticals Inc. (ISPH) (IPO) | 8/3 | $12 | $17.50 | $75.9 | +46% |
|
3-Dimensional Pharmaceuticals Inc. (DDDP) (IPO) | 8/4 | $15 | $38.875 | $86.25 | +159% |
|
Esperion Therapeutics Inc. (ESPR) (IPO) | 8/10 | $9 | $16.062 | $62.1 | +78% |
|
Compugen Ltd. (Israel; CGEN) | 8/14 | $10 | $15.75 | $57.5 | +58% |
|
Westport Resources Investment Services Inc. | Entropin Inc. (OTC BB:ETOP) | 3/21 | $7.25 | $8.625 | $16.2 | +19% |
William Blair & Co. | Sangamo Biosciences- Inc. (SGMO) (IPO) | 4/6 | $15 | $49.25 | $52.5 | +228% |
Large Scale Biology Corp. (LSBC) (IPO) | 8/10 | $17 | $30.906 | $97.75 | +82% |
|
Wit SoundView | Pharsight Corp. (PHST) (IPO) | 8/9 | $10 | $9.625 | $30 | -4% |
Notes: |
|
|||||
* The financings in this chart are for U.S. public offerings only. The data were compiled primarily from BioWorld Financial Watch's monthly financing charts covering the period from Jan. 1 to Aug. 31, 2000. Those charts were published on Feb. 21, March 6, April 10, May 15, June 5, July 10, Aug. 7 and Sept. 11. The gross proceeds totals listed reflect shares sold by selling stockholders, in addition to financing raised for the companies. |
|
|||||
** All prices in U.S. dollars. Offering price per share is adjusted to reflect any post-offering splits. |
|
|||||
1 EntreMed's public offering was part of a shelf registration filed 1/14/00. |
|
|||||
2 The U.S. underwriters for Angiotech's offering are included in this chart. The underwriting syndicate also included Loewen, Ondaatje, McCutcheon Ltd. and Yorkton Securities Inc. in Canada. |
|
|||||
3 The U.S. underwriters for Keryx's offering are included in this chart. WestLB Panmure Ltd. led the offering outside the U.S. |
|
|||||
4 Celgene shares split 3-for-1 on 4/17/00. |
|
|||||
5 Abgenix shares split 2-for-1 on 4/7/00 and 2-for-1 on 7/10/00. |
|
|||||
6 Genome Therapeutics' offering was part of a shelf registration. Tuker Anthony acted as placement agent. |
||||||
